Morgan Stanley analyst Michael Ulz maintained a Hold rating on Alnylam Pharma today and set a price target of $405.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Hold rating due to a combination of factors surrounding Alnylam Pharma’s recent developments. The Phase 2 KARDIA-3 trial results for zilebesiran showed promising reductions in systolic blood pressure, particularly when combined with other antihypertensives. However, the trial did not achieve statistical significance, and the benefits of a higher dose were not evident, which may have tempered enthusiasm.
Additionally, while the safety profile of zilebesiran is encouraging, the full potential of the drug will not be realized until the completion of the Phase 3 ZENITH trial, expected to begin by the end of 2025. This trial aims to further explore cardiovascular outcomes, with a potential launch in 2030. Given these uncertainties and the long timeline before potential market entry, Ulz’s Hold rating reflects a cautious stance, balancing the promising data with the inherent risks and timeframes involved.
Ulz covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Sarepta Therapeutics, and Ionis Pharmaceuticals. According to TipRanks, Ulz has an average return of -1.4% and a 39.09% success rate on recommended stocks.
In another report released on August 19, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $479.00 price target.